The all-stock transaction has created the largest IP portfolio in the psychedelic drug development sector with 28 patents granted and 159 patents pending, alongside the largest data set of systematically studied DMT and dDMT, which adds to Cybin’s (NEO:CYBN NYSE American:CYBN) already existing and robust data on multiple proprietary psychedelic molecules.
Small Pharma’s two proprietary, late-stage clinical programs in development for depression and anxiety disorders, which have demonstrated safety and efficacy, now enable stronger synergies by combining key assets, personnel, capabilities and intellectual property (“IP”), as well as access to world-leading scientific and clinical collaborators.
Cybin will have many eyeballs watching carefully as it scales to Phase 3 development of CYB003 in 1Q 2024, following planned Phase 2 safety and efficacy readout in 4Q 2023 and now has been able to bolt on further intellectual properties and widen its moat in the industry.
Collectively, the combined operating teams of Cybin and Small Pharma create a sector-leading organization with deep expertise in deuterated psychedelic tryptamine-based therapeutics for mental health disorders.
The combination of Cybin and Small Pharma creates an international, clinical-stage leader focused on advancing psychedelic tryptamine-based therapeutics with the potential to transform the treatment paradigm for mental health conditions.
The companies’ combined development portfolios are highly complementary and provide multiple opportunities to create operational and cost synergies. Cybin’s and Small Pharma’s combined dimethyltryptamine (“DMT”) and deuterated DMT (“dDMT”) programs create a world-leading data set on these short-acting psychedelic molecules. Taken together, this transaction creates the largest data set of systematically studied DMT and dDMT and a sector-leading organization with deep expertise on DMT and related compounds globally.
The combined Company will be led by Cybin’s Chief Executive Officer, Doug Drysdale, who brings over 30 years of experience in the healthcare sector. Small Pharma staff will be integrated with the existing Cybin team to create a highly experienced and skilled team that is well-positioned to deliver on the development and clinical execution of the combined pipeline.
“This transaction creates a clear market leader in novel psychedelic therapeutics. The synergy of Cybin and Small Pharma’s development programs, intellectual property, and robust datasets enhances our leadership and expertise in developing potentially best-in-class, deuterated tryptamine-based therapeutics and positions the combined Company to generate long-term value for all stakeholders. We look forward to welcoming our Small Pharma colleagues into the Cybin team,” said Doug Drysdale, Chief Executive Officer of Cybin.
Cybin is a company that is dedicated to changing the landscape of mental healthcare by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens to address the unmet needs of patients suffering from various mental health issues. Cybin is collaborating with a network of renowned partners and pioneers in the field to create safe and effective psychedelic-based therapies. The team at Cybin believes that through their efforts, they can discover, develop, and commercialize innovative therapies that will transform the mental health treatment landscape.